Subscribe to Bayer

The Lead

Proteros and Bayer to Develop New Cardiovascular Drug Compounds

January 8, 2015 8:45 am | News | Comments

The program is based on Proteros' structure-guided lead discovery platform which combines structure analysis, medicinal chemistry and other discovery technologies to drive potency, selectivity, and safety of novel lead compounds.    

Bayer Selects Cardinal Health as U.S. Based Contract Manufacturer for Xofigo Injection

December 18, 2014 1:20 pm | News | Comments

Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract...

Bayer Submits BLA Hemophilia Treatment

December 17, 2014 8:11 am | News | Comments

Bayer HealthCare has submitted a Biologics License Application (BLA) to the U.S. Food and Drug...

FDA Grants Priority Review to Two Bayer Respiratory Meds

November 25, 2014 7:51 am | by The Associated Press | News | Comments

Two medicines Bayer HealthCare Pharmaceuticals Inc. is testing for respiratory disorders will...

View Sample

FREE Email Newsletter

Merck Completes Sale of Consumer Unit to Bayer

October 1, 2014 3:15 pm | News | Comments

Merck has completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion.        

Bayer to Split Off Polymer Division with IPO

September 18, 2014 7:45 am | by The Associated Press | News | Comments

German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The Leverkusen-based company that invented aspirin said Thursday the move would be part of an effort to focus the group on its health care and crop science businesses.

Feds Say Bayer Colon Supplement Makes Bogus Claims

September 12, 2014 3:23 pm | News | Comments

The Department of Justice filed a court motion against the German conglomerate over its advertisements for Phillips' Colon Health, which claims to prevent diarrhea, constipation, gas and bloating. Federal officials say the company does not have reliable scientific evidence to support those claims.


Bayer and Onyx Pharmaceuticals’ Phase 3 Trial of NEXAVAR Misses Study Goals

July 25, 2014 8:26 am | News | Comments

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

Bayer Names U.S. Head of Litigation

July 15, 2014 11:28 am | News | Comments

Bayer today announced the appointment of Malini Moorthy as Head of the Litigation Department in the United States, effective July 30.  She succeeds Kaspar Stoffelmayr, whose three-year assignment ended and has rejoined Bartlit Beck Herman Palenchar & Scott LLP.

Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer

July 7, 2014 8:03 am | News | Comments

Compugen Ltd. has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare. The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen.

Bayer Launches FDA-Approved Soft Chew for Canine Osteoarthritis Pain Management

July 1, 2014 1:35 pm | News | Comments

Bayer HealthCare LLC Animal Health is pleased to announce the launch of quellin (carprofen) soft chewable tablets to help alleviate the pain associated with canine osteoarthritis, one of the most common causes of chronic pain in dogs.   

FDA Approves Bayer's Gadavist as Magnetic Resonance Contrast Agent for Breast Cancer

June 12, 2014 9:18 am | News | Comments

Bayer HealthCare announced today that the FDA has approved a new indication for Gadavist  (gadobutrol) injection for intravenous use with MRI of the breast to assess the presence and extent of malignant breast disease.     


Bayer CEO to Leave Company at End of 2016

June 4, 2014 8:16 am | News | Comments

In line with his own wishes, the contract of Dr. Marijn Dekkers will be extended by just two years on expiration of the initial five-year period. Dekkers cited family reasons for extending his contract only until the end of 2016.    

Boston Scientific to Acquire Interventional Division of Bayer AG

May 15, 2014 8:06 am | News | Comments

In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation has entered into a definitive agreement to acquire the Interventional Division of Bayer AG for $415 million in cash, including fees for transitional services.

Bayer HealthCare Extends Access to Clinical Trial Data

May 14, 2014 10:38 am | News | Comments

By joining the portal, Bayer HealthCare is supporting efforts of the European Medicines Agency (EMA) to increase the transparency of data from clinical studies. As a member company of the pharmaceutical trade associations EFPIA and PhRMA, Bayer is following their declared principles on responsible clinical trial data sharing.

FDA Approves Bayer's Kogenate FS Antihemophilic Factor VIII

May 12, 2014 8:13 am | News | Comments

Bayer HealthCare announced today that the FDA has approved a new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

Bayer to Buy Merck Consumer Business

May 6, 2014 6:36 am | by The Associated Press | News | Comments

Bayer AG says it plans to buy Merck's consumer care business, whose products include the Coppertone suncare range, Claritin allergy medicine and the Dr. Scholl's footcare products, for $14.2 billion.           


Washington University's Birth Control Research Challenged

March 24, 2014 1:41 pm | News | Comments

A Washington University research project that provides free birth control to the poor and uninsured is under scrutiny for its off-label use of a contraceptive insert.              

Bayer Announces Profit of $4.35B

February 28, 2014 4:31 am | by The Associated Press | News | Comments

Bayer AG says its net profit jumped by almost a third last year to 3.19 billion euros ($4.35 billion) as sales hit a record high.                                       

Bayer Clotting Drug Meets Late-Stage Study's Goal

February 19, 2014 8:04 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Bayer HealthCare Pharmaceuticals announced that its experimental, genetically engineered treatment for the most common type of bleeding disorder hemophilia met its main goal of reducing treatment frequency in a late-stage patient study.  

FDA Reconsiders Heart Safety of Common Pain Pills

February 10, 2014 12:12 pm | by Matthew Perrone - AP Health Writer - Associated Press | News | Comments

Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other everyday aches and pains. The Food and Drug Administration holds a two-day meeting starting Monday to examine the latest research on anti-inflammatory medicines called NSAIDS.

Bayer HealthCare to Invest in Manufacturing Operations as Next Step in Recent Animal Health Business Acquisition

January 20, 2014 2:57 pm | News | Comments

Bayer HealthCare LLC has announced that the company will be improving efficiency and investing in its manufacturing operations in Missouri. The company will combine and transfer operations from three locations in the St. Joseph area to one beginning this year.

Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration

January 13, 2014 4:16 pm | News | Comments

Regeneron Pharmaceuticals and Bayer HealthCare today announced an agreement to jointly develop an innovative antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a potential combination therapy with EYLEA (aflibercept) for the treatment of wet age-related macular degeneration (wet AMD).

Bayer to Acquire Cancer Specialist Algeta

December 19, 2013 5:11 am | by The Associated Press | News | Comments

Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based company to nearly $2.9 billion. The two firms said Thursday drug and chemical company Bayer will make a cash offer of 362 kroner ($59.24) per Algeta share.

Moberg Pharma Signs Deal to Acquire OTC Brands in the U.S.

December 6, 2013 8:21 am | News | Comments

Moberg Pharma AB has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources.

Bayer Makes Offer for Norway's Algeta

November 26, 2013 6:01 am | by The Associated Press | News | Comments

Norway-based cancer drug maker Algeta ASA says it has received a preliminary takeover offer from Germany's Bayer AG that values the company at about $2.4 billion. Algeta said in a statement Tuesday that the offer is for 336 kroner ($55.11) per share; the company has nearly 44 million shares.

FDA Approves Bayer Pill for Thyroid Cancer

November 25, 2013 8:21 am | News | Comments

The FDA has expanded approval of a Bayer drug to treat patients with thyroid cancer. Bayer's pill Nexavar is already approved to treat kidney cancer and liver cancer that cannot be surgically removed. Now the FDA has approved the drug to treat cancerous growth of the thyroid gland, which is located in the neck.

New Drugs A Boost For Bayer

October 31, 2013 10:37 am | by Davud McHugh, AP | News | Comments

Drug and materials company Bayer AG says net profit rose 42 percent as sales increased for its new drugs aimed at preventing blood clots and treating the eye disease macular degeneration, while one-time expenses dropped. Net profit reached $1.01 billion.

Bayer Says FDA Approves Lung Disease Drug Adempas

October 9, 2013 9:58 am | by The Associated Press | News | Comments

Bayer HealthCare said Tuesday its drug Adempas has been approved as a treatment for two types of pulmonary hypertension, or high blood pressure in the arteries of the lungs. Bayer said it is already launching the drug, and called Adempas the first drug approved by the Food and Drug Administration...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.